Blood Coagulation Abnormalities in COVID-19 (Corona Virus Disease-19) Patients

Blood Coagulation Abnormalities in COVID-19 Patients and Correlation With Severity

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04982263

Enrollment

125

Registered

2021-07-29

Start date

2021-02-01

Completion date

2021-05-31

Last updated

2021-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

The role of the coagulation parameters in predicting the severity of COVID-19 disease will be assessed

Detailed description

In COVID-19 patients the coagulation parameters Prothrombin concentration (PC), Activated Partial Thromboplastin Time (aPTT), D Dimer, Antithrombin III (ATIII) and Fibrinogen are measured and correlation with disease severity is to be investigated

Interventions

DIAGNOSTIC_TESTBlood coagulation profile

Venous blood sample for measurement of blood coagulation profile

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

● Confirmed cases with COVID 19

Exclusion criteria

● Known history of blood coagulopathy disorder

Design outcomes

Primary

Measure	Time frame	Description
correlation of disease severity with results of laboratory test	Baseline results of coagulation profile and baseline disease severity assessment	The results of blood coagulation profile will be correlated with degree of severity of illness

Secondary

Measure	Time frame	Description
Agreement of abnormalities in coagulation profile with measured inflammatory markers	baseline measurement of inflammatory markers	The inflammatory markers will be measured and correlation with abnormalities in coagulation profile will be assessed

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026